Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 2001 April; 84(7): 886–891.
PMCID: PMC2363838

Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial


Chemotherapy is not effective for hepatocellular carcinoma (HCC). HMG-CoA redutase inhibitors have cytostatic activity for cancer cells, but their clinical usefulness is unknown. To investigate whether pravastatin, a potent HMG-CoA reductase inhibitor, prolongs survival in patients with advanced HCC, this randomized controlled trial was conducted between February 1990 and February 1998 at Osaka University Hospital. 91 consecutive patients <71 years old (mean age 62) with unresectable HCC were enroled in this study. 8 patients were withdrawn because of progressive liver dysfunction; 83 patients were randomized to standard treatment with or without pravastatin. All patients underwent transcatheter arterial embolization (TAE) followed by oral 5-FU 200 mg−1d for 2 months. Patients were then randomly assigned to control (n = 42) and pravastatin (n = 41) groups. Pravastatin was administered at a daily dose of 40 mg. The effect of pravastatin on tumour growth was assessed by ultrasonography. Primary endpoint was death due to progression of HCC. The duration of pravastatin administration was 16.5 ± 9.8 months (mean ± SD). No patients in either group were lost to follow-up. Median survival was 18 months in the pravastatin group versus 9 months in controls (P = 0.006). The Cox proportional hazards model showed that pravastatin was a significant factor contributing to survival. Pravastatin prolonged the survival of patients with advanced HCC, suggesting its value for adjuvant treatment. © 2001 Cancer Research Campaign

Keywords: hepatocellular carcinoma, pravastatin, HMG-CoA reductase inhibitor, survival

Full Text

The Full Text of this article is available as a PDF (82K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini GB. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation. 1995 Nov 1;92(9):2419–2425. [PubMed]
  • Cavalli F, Rozencweig M, Renard J, Goldhirsch A, Hansen HH. Phase II study of oral VP-16-213 in hepatocellular carcinoma. Eur J Cancer Clin Oncol. 1981 Oct;17(10):1079–1082. [PubMed]
  • Charnsangavej C, Chuang VP, Wallace S, Soo CS, Bowers T. Work in progress: transcatheter management of primary carcinoma of the liver. Radiology. 1983 Apr;147(1):51–55. [PubMed]
  • Choi TK, Lee NW, Wong J. Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy. Cancer. 1984 Feb 1;53(3):401–405. [PubMed]
  • Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Semin Liver Dis. 1995 Feb;15(1):64–69. [PubMed]
  • El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999 Mar 11;340(10):745–750. [PubMed]
  • Falkson G, MacIntyre JM, Moertel CG, Johnson LA, Scherman RC. Primary liver cancer. An Eastern Cooperative Oncology Group Trial. Cancer. 1984 Sep 15;54(6):970–977. [PubMed]
  • Gibbs JB, Pompliano DL, Mosser SD, Rands E, Lingham RB, Singh SB, Scolnick EM, Kohl NE, Oliff A. Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo. J Biol Chem. 1993 Apr 15;268(11):7617–7620. [PubMed]
  • Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990 Feb 1;343(6257):425–430. [PubMed]
  • Goldstein JL, Helgeson JA, Brown MS. Inhibition of cholesterol synthesis with compactin renders growth of cultured cells dependent on the low density lipoprotein receptor. J Biol Chem. 1979 Jun 25;254(12):5403–5409. [PubMed]
  • Habenicht AJ, Glomset JA, Ross R. Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and swiss 3T3 cells stimulated to divide by platelet-derived growth factor. J Biol Chem. 1980 Jun 10;255(11):5134–5140. [PubMed]
  • James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS, Crowley CW, Lucas BK, Levinson AD, Marsters JC., Jr Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science. 1993 Jun 25;260(5116):1937–1942. [PubMed]
  • Kandutsch AA, Chen HW. Consequences of blocked sterol synthesis in cultured cells. DNA synthesis and membrane composition. J Biol Chem. 1977 Jan 25;252(2):409–415. [PubMed]
  • Kawata S, Takaishi K, Nagase T, Ito N, Matsuda Y, Tamura S, Matsuzawa Y, Tarui S. Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepatocellular carcinoma: possible mechanism for alteration of cholesterol biosynthesis. Cancer Res. 1990 Jun 1;50(11):3270–3273. [PubMed]
  • Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science. 1993 Jun 25;260(5116):1934–1937. [PubMed]
  • Maltese WA, Defendini R, Green RA, Sheridan KM, Donley DK. Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Clin Invest. 1985 Nov;76(5):1748–1754. [PMC free article] [PubMed]
  • Matsuda Y, Kawata S, Nagase T, Maeda Y, Yamasaki E, Kiso S, Ishiguro H, Matsuzawa Y. Interleukin-6 in transcatheter arterial embolization for patients with hepatocellular carcinoma. Effects of serine protease inhibitor. Cancer. 1994 Jan 1;73(1):53–57. [PubMed]
  • Okuda K. Hepatocellular carcinoma: recent progress. Hepatology. 1992 May;15(5):948–963. [PubMed]
  • Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res. 1987 Sep 15;47(18):4967–4972. [PubMed]
  • Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 Nov 16;333(20):1301–1307. [PubMed]
  • Simonetti RG, Cammà C, Fiorello F, Politi F, D'Amico G, Pagliaro L. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci. 1991 Jul;36(7):962–972. [PubMed]
  • Sinensky M, Beck LA, Leonard S, Evans R. Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis. J Biol Chem. 1990 Nov 15;265(32):19937–19941. [PubMed]
  • Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med. 1999 Jul;5(7):810–816. [PubMed]
  • Stefanini GF, Amorati P, Biselli M, Mucci F, Celi A, Arienti V, Roversi R, Rossi C, Re G, Gasbarrini G. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience. Cancer. 1995 May 15;75(10):2427–2434. [PubMed]
  • Tsujita Y, Kuroda M, Shimada Y, Tanzawa K, Arai M, Kaneko I, Tanaka M, Masuda H, Tarumi C, Watanabe Y, et al. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim Biophys Acta. 1986 Jun 11;877(1):50–60. [PubMed]
  • Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology. 1983 Aug;148(2):397–401. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK